A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Xeris Biopharma Holdings, Inc. along with its subsidiaries, is referenced herein as the "Company", "Xeris", "Xeris Biopharma", "we" or "our". Throughout this document, unless otherwise noted, references to Gvoke include Gvoke PFS, Gvoke HypoPen, and Gvoke Kit. We are a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. We offer Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis ("PPP"). We are advancing our Phase 3-ready pipeline product, XP-8121, once-weekly subcutaneous ("SC") levothyroxine, which leverages our proprietary technology XeriSol.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 292M | 292M | 203M | 164M | 110M | - |
| Net Income | 554K | 554K | -55M | -62M | -95M | -123M |
| EPS | $0.00 | $0.00 | $-0.37 | $-0.45 | $-0.70 | $-1.55 |
| Free Cash Flow | 28M | 28M | -38M | -49M | -103M | -97M |
| ROIC | 20.2% | 57.7% | -29.3% | -33.8% | -40.8% | -67.0% |
| Gross Margin | 85.4% | 85.4% | 81.9% | 82.5% | 79.5% | - |
| Debt/Equity | 16.10 | 16.10 | -8.35 | -28.15 | 4.14 | 0.92 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 25M | 25M | -34M | -44M | -82M | -115M |
| Operating Margin | 8.5% | 8.5% | -16.6% | -26.8% | -74.3% | - |
| ROE | 4.0% | 4.0% | - | - | -209.5% | -190.3% |
| Shares Outstanding | 172M | 172M | 148M | 138M | 135M | 79M |
| Metric | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | N/A | N/A | 110M | 164M | 203M | 292M | 292M |
| Gross Margin | N/A | N/A | 79.5% | 82.5% | 81.9% | 85.4% | 85.4% |
| R&D | 21M | 25M | 21M | 22M | 26M | 31M | 31M |
| SG&A | 74M | 126M | 138M | 146M | 163M | 182M | 182M |
| EBIT | -84M | -115M | -82M | -44M | -34M | 25M | 25M |
| Op. Margin | N/A | N/A | -74.3% | -26.8% | -16.6% | 8.5% | 8.5% |
| Net Income | -91M | -123M | -95M | -62M | -55M | 554K | 554K |
| Net Margin | N/A | N/A | -85.9% | -38.0% | -27.0% | 0.2% | 0.2% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | -75.5% | -67.0% | -40.8% | -33.8% | -29.3% | 57.7% | 20.2% |
| ROE | -378.2% | -190.3% | -209.5% | N/A | N/A | 4.0% | 4.0% |
| ROA | -57.3% | -40.3% | -27.5% | -19.3% | -17.0% | 0.2% | 0.1% |
| Cash Flow | |||||||
| Op. Cash Flow | -81M | -96M | -103M | -47M | -37M | 29M | 29M |
| Free Cash Flow | -81M | -97M | -103M | -49M | -38M | 28M | 28M |
| Owner Earnings | -90M | -108M | -116M | -59M | -57M | 4.9M | 4.9M |
| CapEx | 377K | 1.1M | 524K | 2.3M | 868K | 696K | 696K |
| Maint. CapEx | 1.5M | 1.3M | 1.4M | 1.5M | 1.2M | 1.3M | 1.3M |
| Growth CapEx | 0 | 0 | 0 | 776K | 0 | 0 | 0 |
| D&A | 1.5M | 1.3M | 1.4M | 1.5M | 1.2M | 1.3M | 1.3M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 2.4% | 2.4% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 8.3M | 11M | 12M | 11M | 18M | 22M | 22M |
| Debt Repayment | 25M | 0 | 43M | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | -47M | -14M | 65M | 118M | 104M | -1.7M | 109M |
| Cash & Equiv. | 38M | 67M | 122M | 67M | 72M | 111M | 111M |
| Long-Term Debt | 87M | 88M | 187M | 191M | 217M | 220M | 220M |
| Debt/Equity | 2.58 | 0.92 | 4.14 | -28.15 | -8.35 | 16.10 | 16.10 |
| Interest Coverage | -7.8 | -16.0 | -5.8 | -1.7 | -1.1 | 0.9 | 0.9 |
| Equity | 34M | 95M | 45M | -6.8M | -30M | 14M | 14M |
| Total Assets | 159M | 304M | 345M | 323M | 323M | 384M | 384M |
| Total Liabilities | 125M | 209M | 299M | 329M | 353M | 370M | 370M |
| Intangibles | 0 | 154M | 143M | 133M | 122M | 111M | 111M |
| Retained Earnings | -337M | -460M | -555M | -617M | -672M | -671M | -671M |
| Working Capital | 124M | 64M | 113M | 61M | 67M | 131M | 131M |
| Current Assets | 152M | 143M | 187M | 156M | 168M | 240M | 240M |
| Current Liabilities | 28M | 79M | 74M | 95M | 100M | 110M | 110M |
| Per Share Data | |||||||
| EPS | -2.14 | -1.55 | -0.70 | -0.45 | -0.37 | 0.00 | 0.00 |
| Owner EPS | -0.67 | -1.37 | -0.86 | -0.43 | -0.38 | 0.03 | 0.03 |
| Book Value | 0.25 | 1.20 | 0.33 | -0.05 | -0.20 | 0.08 | 0.08 |
| Cash Flow/Share | -0.59 | -1.21 | -0.76 | -0.34 | -0.25 | 0.17 | 0.01 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 135.5M | 79.2M | 135.2M | 138.3M | 148.2M | 172.4M | 172.4M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| P/FCF | N/A | N/A | N/A | N/A | N/A | 45.5 | 36.9 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | 51.0 | 45.7 |
| Price/Book | 21.7 | 2.0 | 3.4 | N/A | N/A | 92.8 | 75.2 |
| Price/Sales | N/A | N/A | 2.4 | 1.7 | 1.9 | 3.4 | 3.5 |
| FCF Yield | -11.1% | -50.0% | -67.1% | -15.1% | -7.4% | 2.2% | 2.7% |
| Market Cap | 732M | 193M | 154M | 326M | 508M | 1.3B | 1.0B |
| Avg. Price | 4.21 | 3.58 | 1.92 | 1.97 | 2.59 | 5.78 | 5.97 |
| Year-End Price | 5.40 | 2.44 | 1.14 | 2.36 | 3.43 | 7.37 | 5.97 |
Xeris Biopharma Holdings, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 36.9x vs a median of 45.5x. The company's 5-year average gross margin is 82.3%.
Xeris Biopharma Holdings, Inc. (XERS) has a 5-year average return on invested capital (ROIC) of -22.6%. This is below average and may indicate limited pricing power.
Xeris Biopharma Holdings, Inc. (XERS) has a market capitalization of $1.0B. It is classified as a small-cap stock.
Xeris Biopharma Holdings, Inc. (XERS) does not currently pay a regular dividend.
Xeris Biopharma Holdings, Inc. (XERS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Xeris Biopharma Holdings, Inc. (XERS) reported annual revenue of $292 million in its most recent fiscal year, based on SEC EDGAR filings.
Xeris Biopharma Holdings, Inc. (XERS) has a net profit margin of 0.2%. This is a modest margin.
Xeris Biopharma Holdings, Inc. (XERS) generated $28 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Xeris Biopharma Holdings, Inc. (XERS) has a debt-to-equity ratio of 16.10. This indicates higher leverage, which may increase financial risk.
Xeris Biopharma Holdings, Inc. (XERS) has a return on equity (ROE) of 4.0%. This indicates moderate shareholder returns.
Xeris Biopharma Holdings, Inc. (XERS) has a 5-year average gross margin of 82.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 6 years of financial data for Xeris Biopharma Holdings, Inc. (XERS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Xeris Biopharma Holdings, Inc. (XERS) has a book value per share of $0.08, based on its most recent annual SEC filing.